Application of Recombinant VII Activated Coagulation Factor for Children with Resistant Coagulopathy Caused Sepsis
Abstract
Purpose: To investigate the effectiveness of recombinant VII activated coagulation factor in complex therapy of children with resistant coagulopathy caused by sepsis.
Materials and Methods: 38 children from 2 months to 17 years old were investigated with resistant coagulopathy caused by sepsis and using of recombinant VII activated coagulation factor. Patients were divided into 2 groups. The first group concluded the children before 1 year old; the second group concluded the children after 1 year old.
Results: The children of first group revealed the improvement of clinical and laboratory status after two intravenous applications (2 hours between using) of recombinant VII activated coagulation factor. The single use of recombinant VII activated coagulation factor was sufficient for children of second group. There was no effect in both groups of children with sepsis and multiorgan failure.
Summary: The application of recombinant VII activated coagulation factor is effective for therapy of children with resistant coagulopathy caused by severe sepsis.
About the Authors
N. Bgane
Kuban State Medical University
Russian Federation
Russian Federation
Department of Anaesthesiology, Critical Care Medicine and Transfusiology of Professional and Training Development Department
4 Sedina st., Krasnodar, 350063
A. Trembach
Kuban State Medical University
Russian Federation
Russian Federation
Department of Anaesthesiology, Critical Care Medicine and Transfusiology of Professional and Training Development Department
4 Sedina st., Krasnodar, 350063
References
1. Hedner U. Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent// Clinical advances in hematology & oncology. – 2003. - Feb; 1 (2). – P.112-119
2. Veldman A. Hoffman M. Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa// Current medical chemistry. – 2003. - May; 10 (10). – P.797-811
3. Кобец Т.В., Бассалыго Г.А. Курс лекций по детской гематологии. – Симферополь, 2000.-77с.
4. Заболотских И.Б., Синьков С.В., Шапошников С.А. Диагностика и коррекция расстройств системы гемостаза. – М.: Практическая медицина, 2008.–331с.
5. Taylor F. B., Ton C. H., Hoots W. K., et al. Scientific and Standardization Committe Communications: Towards a Definition. Clinical and Laboratory Criteria, and a Scoring System for Disseminated intravascular Coagulation. Scientific Subcommitte on Disseminated intravascular Coagulation (DIG) of the international Society on Thrombosis and Haemostasis-2009
6. Kheirabadi BS et al. In vitro effect of activated recombinant factor VII (rFVIIa) on coagulation properties of human blood at hypothermic temperatures// The Jornal of Trauma. – 2007. - Nov; 63(5). – P.1079-1086
7. Kirpalani H. Lennox H. Huang. Manual of pediatric intensive care. - PMPH-USA, 2009.-977p.
8. Hendriks HG et al. Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantion// Blood coagulation fibrinolysis an jornal in haemostasis and trombosis. – 2002. - Jun; 13(4). – P.309-313
9. Sorensen B. Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond// Seminars in hematology. – 2004. - Jan; 41(1Suppl). – P.140-144
10. Alten JA et al. Pediatric off-label use of recombinant factor VIIa// Pediatrics. – 2009. - Mar; 123(3). – P.1066-1072
Review
For citations:
Bgane N., Trembach A. Application of Recombinant VII Activated Coagulation Factor for Children with Resistant Coagulopathy Caused Sepsis. Medical Herald of the South of Russia. 2010;(2):38-40. (In Russ.)
Views:
277
Email this article 